Financial Reports

Revenue

$255m

↑ 19.4% on FY23

Underlying NPAT1,3

$29.9m

↑ 17.4% on FY23

Underlying EBITDA1,2

$62.8m

↑ 17.5% on FY23

Underlying EBIT1,2

$43.3m

↑ 13.7% on FY23

1. Non-IFRS measure.
2. Refer to page 34 for reconciliation of Reported EBITDA, EBIT, and NPAT to Underlying EBITDA, EBIT, and NPAT.
3. NPAT including minority interest.
4. Clinical pregnancy rate per embryo transferred (women aged <43 years)

FY24 Profit & Loss Overview

Underlying ($m)
FY24
FY23
% Change
Group Revenue 255.0 213.6 19.4%
Underlying EBITDA 1,2 62.8 53.4 17.5%
Underlying EBIT 1,2 43.3 38.1 13.7%
Underlying NPAT 1,2,3 29.9 25.5 17.4%
Reported ($m)
Reported EBITDA 1 13.2 48.5 (72.7%)
Depreciation & amortisation (18.6) (15.4) 2.1%
Reported EBIT (5.3) 33.1 (116.1%)
Net finance costs (5.3) (3.3) 62.1%
Reported Profit before tax (10.7) 29.8 (135.7%)
Income tax expense (4.7) (7.8) (159.8%)
Reported NPAT 3 (5.9) 22.0 (127.1%)

FY24 Cash Flow Overview

($m)
FY24
FY23
% Change
Reported EBITDA 13.2 48.5 (72.7%)
Movement in working capital 49.1 (0.0) 100%
Income taxes paid (9.8) (9.4) 4.4%
Net operating cash flow (post tax) 39.1 31.9 22.6%
Capital expenditure (21.7) (27.8) 22.0%
Payments for businesses/minority interest (17.1) (12.7) (34.7%)
Cash flow from investing activities (38.8) (40.5) (4.2%)
Free Cash flow4 13.7 (1.4) 1090%
Dividends paid (18.3) (17.1) (6.9%)
Interest on borrowings5 (2.6) (1.2) (118.5%)
Payments of lease liabilities (10.5) (9.2) (14.5%)
Proceeds of borrowings 21.0 29.0 27.6%
Cash flow from financing activities (10.4) 1.5 (789.1%)
Net cash flow movement 3.3 0.1 2627.9%
Closing cash balance 11.3 8.0 41.6%

1. Non-IFRS measure.
2. Refer to page 34 for reconciliation of Reported EBITDA, EBIT, and NPAT to Underlying EBITDA, EBIT, and NPAT.
3. NPAT including minority interest.
4. Free Cash Flow is Net Operating cash flow (post-tax) less Cash Flow from investing activities.
5. Including capitalised bank fees

Financial Reports Download